

WHO recommendation on Routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth







# WHO recommendation on Routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth





WHO recommendation on routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth

ISBN 978-92-4-001392-6 (electronic version) ISBN 978-92-4-001393-3 (print version)

### © World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

**Suggested citation.** WHO recommendation on routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at http://apps.who.int/iris.

**Sales, rights and licensing.** To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

## **Contents**

Ack	nowle	dgements	\	
Acr	onyms	and abbreviations	V	
Exe	cutive	summary	vi	
	Intro	duction	vi	
	Targ	Target audience		
	Guic	leline development methods	vi	
	Reco	ommendation	vii	
1.	Introduction			
	1.1	Background		
	1.2	Rationale and objectives		
	1.3	Target audience	2	
	1.4	Scope of the recommendation	2	
	1.5	Persons affected by the recommendation	2	
2.	Methods			
	2.1	Executive Guideline Steering Group (GSG)	3	
	2.2	WHO Steering Group	3	
	2.3	Guideline Development Group (GDG)	3	
	2.4	Evidence Synthesis Group (ESG)	۷	
	2.5	External partners and observers	۷	
	2.6	External Review Group (ERG)	۷	
	2.7	Identification of priority questions and outcomes	۷	
	2.8	Evidence identification and retrieval	5	
	2.9	Certainty assessment and grading of the evidence	5	
	2.10	Formulation of the recommendation	6	
	2.11	Management of declarations of interests	8	
	2.12	Decision-making during the GDG meeting	8	
	2.13	Document preparation	ç	
	2.14	Peer review	ç	
3.	Reco	ommendation and supporting evidence	10	
4.	Dissemination, adaptation and implementation of the recommendation			
	4.1	Recommendation dissemination	12	
	4.2	Adaptation	12	
	4.3	Implementation considerations	13	
5.	Rese	earch implications	13	
6.	Applicability issues			
	6.1.	Anticipated impact on the organization of care and resources	14	
	6.2.	Monitoring and evaluating guideline implementation	14	
7.	Upd	ating the recommendation	15	
8.	Refe	rences	16	

Annex 1.	External experts and who staff involved in the preparation of the recommendation	19
Annex 2.	Priority outcomes used in decision-making	22
Annex 3.	Summary and management of declared interests from GDG members	23
Annex 4.	Evidence to Decision framework	25

## *ICKNOWLEDGEMENTS*

## **Acknowledgements**

The World Health Organization (WHO) Department of Sexual and Reproductive Health and Research and Department of Maternal, Newborn, Child and Adolescent Health and Ageing gratefully acknowledge the contributions of many individuals and organizations to the updating of this recommendation. Work on this update was coordinated by Fernando Althabe, Tina Lavin, Olufemi Oladapo, Joshua Vogel and Mariana Widmer of the Department of Sexual and Reproductive Health and Research.

WHO extends its sincere thanks to Oluwarotimi Ireti Akinola, Brendan Carvalho, Melania Amorim, Catherine Deneux-Tharaux, Tippawan Liabsuetrakul, Martin Meremikwu, Suellen Miller, Mari Nagai, Hayfaa Wahabi, Dilys Walker and Andrew Weeks who served as members of the Guideline Development Group (GDG), and to Ashraf Nabhan (Chair) for leading the meeting. We also thank Christine East, Gill Gyte, Justus Hofmeyr, Syeda Batool Mazhar, Enrique Oyarzun and Qian Xu, who were members of the External Review Group (ERG). WHO also gratefully acknowledges the contribution of the members of the Executive Guideline Steering Group (GSG).

Edgardo Abalos, Anna Cuthbert, Virginia Diaz, Kenneth Finlayson, Leanne Jones, Frances Kellie and Myfanwy Williams reviewed the scientific evidence, prepared the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tables and drafted the narrative summary of the evidence. Fernando Althabe, Olufemi Oladapo, Mariana Widmer and Joshua Vogel revised the narrative summaries and double-checked the corresponding GRADE tables and prepared the Evidence to Decision (EtD) frameworks. The ERG peer reviewed the final document prior to executive clearance by WHO and publication.

We acknowledge the various organizations that were represented by observers, including Deborah Armbruster (United States Agency for International Development [USAID]), Ingela Wiklund (International Confederation of Midwives [ICM]) and Carlos Fuchtner (International Federation of Gynecology and Obstetrics [FIGO]). We also appreciate the contributions of staff at the WHO regional offices, including Nino Berdzuli, Bremen De Mucio, Hayfa Elamin, Chandani Anoma Jayathilaka, Ramez Khairi Mahaini, Howard Sobel and Claudio Sosa.

WHO acknowledges the financial support for this work received from USAID and the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction the Department of Sexual and Reproductive Health and Research. WHO emphasizes that donors do not participate in any decision related to the guideline development process, including the composition of research questions, membership of the guideline development groups, conducting and interpretation of systematic reviews, or formulation of the recommendations. The views of the funding bodies have not influenced the content of this recommendation.

## **Acronyms and abbreviations**

CerQUAL Confidence in the Evidence from Reviews of Qualitative Research

DOI declaration of interest
ERG Evidence Review Group
ESG Evidence Synthesis Group

EtD Evidence to Decision

FIGO International Federation of Gynecology and Obstetrics

GDG Guideline Development Group

GRADE Grading of Recommendations Assessment, Development and Evaluation

GSG Guideline Steering Group

HRP UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research,

Development and Research Training in Human Reproduction

ICM International Confederation of Midwives

IM intramuscular

IU international units

IV intravenous

MPH-GDG WHO Maternal and Perinatal Health Guideline Development Group

PICO population (P), intervention (I), comparator (C), outcome (O)

PPH postpartum haemorrhage

UNDP United Nations Development Programme

UNIFPA United Nations Population Fund
UNICEF United Nations Children's Fund

USAID United States Agency for International Development

WHO World Health Organization

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5\_24283



